Risk factors

The company faces heavy regulatory exposure across direct selling laws, product formulations, and global trade compliance. Revenue heavily depends on the productivity, retention, and advertising compliance of independent consultants. International exposure is significant, with joint venture risks in China and reliance on foreign currencies.

Nuwellis faces significant risks related to maintaining its Nasdaq listing, managing operating cash burn, and complying with complex financial instrument accounting.

OppFi faces risks heavily concentrated on reliance on bank partners for 100% of originations, unproven machine learning underwriting models, and heavy dependence on a single unsecured personal loan product.

Ovid Therapeutics faces significant cash burn, holding $53.1 million against an accumulated deficit of $304.3 million.

Owlet faces significant risks from historical operating losses and accumulated deficits totaling $268.2 million as of December 31, 2024. The company relies heavily on a limited number of retailers, with top three customers generating 58% of 2024 revenue. Products depend heavily on Apple and Google app stores, third-party manufacturing, and strict FDA medical device regulations.

Paymentus operates in an evolving bill payment market facing intense competition from legacy financial institutions and tech providers.

Clinical-stage biotech focused on bempikibart after discontinuing ADX-097 in February 2025. Highly reliant on raising capital, patent protection, and FDA regulatory approvals to survive.

Rapport Therapeutics faces high capital requirements and clinical trial execution risks for its nervous system drug candidates.

SandRidge Energy faces concentrated operational risks in the Mid-Continent region and relies heavily on volatile commodity prices. The company carries $1.6 billion in federal net operating losses protected by a Tax Benefits Preservation Plan extending to July 2026.

International agri-foods and restaurant operations expose the company to currency fluctuations, geopolitical unrest, and strict global regulations. Growth relies heavily on acquisitions, third-party consultants like Aggia LLC FZ, and external financing facilities like the Yorkville SEPA.

Supply chain disruptions and raw material price volatility threaten manufacturing and profit margins across segments. Acquisitions and integration complexities drive operational risks across branded products and contact centers. Significant indebtedness of $86.0 million and $13.6 million in unfunded SERP obligations constrain capital flexibility.

Heavy reliance on U.S. Government contracts like BARDA for TPOXX revenues creates significant concentration risk. International expansion faces hurdles in regulatory approvals and managing third-party partners like Meridian. Intellectual property protection and complex global compliance are vital for future growth.